在 FDA 认为 3 期试验不足后，Actinium 面临潜在的证券欺诈调查，导致股票下跌。 Actinium faces potential securities fraud investigation after FDA deems Phase 3 trial insufficient, causing stock drop.

Actinium Pharmaceuticals 面临 Pomerantz LLP 的潜在证券欺诈调查，此前 FDA 对其计划在 r/r AML 中提交 Iomab-B 的 BLA 申请进行了负面更新。 Actinium Pharmaceuticals faces a potential securities fraud investigation by Pomerantz LLP following a negative FDA update on its planned BLA filing for Iomab-B in r/r AML. SIERRA第3阶段的审判被认为不足以提交BLA文件。 The Phase 3 SIERRA trial was deemed insufficient for BLA filing. 宣布后,Actinium的库存下降了59.81%。 After the announcement, Actinium's stock dropped 59.81%. Pomerantz LLP建议投资者联系他们了解进一步信息。 Pomerantz LLP advises investors to contact them for further info.